1000 Newport Center Drive, 231
About jCyteBased in Orange County, California, jCyte is committed to developing therapies for incurable retinal diseases. The company was founded by physician researchers Henry Klassen, MD, PhD, and Jing Yang, MD, PhD in 2012. Their work has been supported by the California Institute for Regenerative Medicine (CIRM), the National Institutes of Health (NIH) and other organizations.
Founders: Henry J. Klassen and Jing Yang
CEO: Paul Bresge
COO: Terry O’Neal
Tweets by jCyte
13 articles with jCyte
jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations.
jCyte, Inc . announced the continued expansion of the company’s executive management team with the appointment of Adrian Morris as Chief Development Officer.
jCyte, Inc. announced the further expansion of the company’s executive management team with the appointment of Adam Walsh, M.D. as Chief Financial Officer.
jCyte, Inc. , a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the further expansion of the company’s executive management team with the appointment of John Sholar as General Counsel. Mr. Sholar brings to jCyte more than 20 years of industry experience, serving as the head of North American legal
jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy
jCyte, Inc . today announced presentations at the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Following the Phase 2b headline results of jCell therapy in retinitis pigmentosa (RP) first presented at the American Society of Retinal Specialists (ASRS) Annual Meeting, further detailed analyses from this study, the largest randomized clinical trial ever conducted
jCyte Inc. presented the results from its Phase IIb study and a detailed analysis of the study’s optical coherence tomography (OCT) data last week at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations
Company appoints Dr. Samir Mody as Chief Commercial Officer, Dr. Friedrich Asmus as SVP, Clinical Development & Medical Affairs and Joel Centeno as SVP, Manufacturing, Quality & Supply Chain.
Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidence of potential benefit in patients as an investigational treatment for retinitis pigmentosa agnostic to genetic subtype Based on these results, jCyte plans to initiate a pivotal study in 2021 jCell is a first-in-class investigational treatment which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Dr
jCyte Inc. Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting
jCyte Inc. , a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today that results from the Phase 2b clinical trial of jCell in retinitis pigmentosa will be presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting, held July 24-26, 2020. jCell is a first-in-class investigation
jCyte Inc ., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory Board (SAB) comprised of world-renowned retinal physicians to provide external scientific review and high-level counsel on the Company’s research and development programs. The SAB will continue to work closely with the jCyte leadership team, as the Comp
Presented by David S. Boyer, MD, at the annual Ophthalmology Innovation Summit in November, the 12-month study showed a favorable safety profile and indications of potential benefit.